Sanofi to acquire Synthorx for $2.5bn to strengthen immuno-oncology pipeline

This article was originally published here

Headquartered in California, Synthorx is focused on developing therapies for cancer and autoimmune disorders. Sanofi is offering to buy the biotechnology company at $68 per share. THOR-707, the

The post Sanofi to acquire Synthorx for $2.5bn to strengthen immuno-oncology pipeline appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply